Derivative works — US Patent 12502357

As a Senior Patent Strategist and Research Engineer, I have analyzed the core inventive concepts within US patent 12502357. The following document constitutes a defensive disclosure designed to create prior art against potential future inventions that represent incremental improvements or variations on the foundational technology.

This disclosure is based on the core inventive concept of US patent 12502357: A pharmaceutical composition comprising a solid amorphous dispersion of a poorly soluble active pharmaceutical ingredient (API), exemplified by enzalutamide, and a concentration-enhancing polymer.

Defensive Disclosure and Prior Art Generation

1. Material & Component Substitution

Derivative 1.1: Amorphous Dispersion Utilizing Mesoporous Silica Carriers

Enabling Description: An alternative to a polymer-matrix solid dispersion is the adsorption of the API onto a high-surface-area inorganic carrier. Enzalutamide is dissolved in a suitable volatile solvent (e.g., acetone, methanol). This solution is then mixed with a mesoporous silica carrier, such as SBA-15 or MCM-41, having a pore diameter between 5 nm and 20 nm. The solvent is evaporated under vacuum, causing the enzalutamide to deposit as a monolayer or amorphous nanocluster within the silica pores. This spatial confinement prevents nucleation and crystallization. The final product is a free-flowing powder comprising enzalutamide-loaded mesoporous silica, which can be blended with disintegrants and lubricants for direct compression into tablets. This composition enhances dissolution by maximizing the surface area of the amorphous drug exposed to the dissolution medium.

graph TD
    A[Enzalutamide] --> C{Dissolve in Acetone};
    B[Mesoporous Silica Carrier, e.g., SBA-15] --> D{Mix with Enzalutamide Solution};
    C --> D;
    D --> E{Solvent Evaporation under Vacuum};
    E --> F[Amorphous Enzalutamide confined in Silica Pores];
    F --> G{Blend with Excipients};
    G --> H[Direct Compression Tablet];

Derivative 1.2: Co-Amorphous Systems with Small-Molecule Excipients

Enabling Description: Instead of a polymer, a low-molecular-weight, pharmaceutically acceptable excipient (a "co-former") is used to create a co-amorphous system with enzalutamide. The co-former is selected based on its ability to form strong intermolecular interactions (e.g., hydrogen bonds) with enzalutamide, such as an amino acid (e.g., arginine, tryptophan) or a carboxylic acid (e.g., citric acid, tartaric acid). Enzalutamide and the co-former are co-dissolved in a solvent in a specific molar ratio (e.g., 1:1 or 1:2) and then rapidly solidified using spray-drying or cryo-milling. The resulting co-amorphous powder has a single glass transition temperature (Tg) higher than that of amorphous enzalutamide alone, indicating a stable, homogeneous mixture that inhibits crystallization and enhances solubility.

classDiagram
    class CoAmorphousSystem {
        +singleGlassTransitionTemp : float
        +molarRatio : string
    }
    class Enzalutamide {
        -molecularWeight: 464.44
    }
    class CoFormer {
        <<Excipient>>
        +type: AminoAcid
        +example: Arginine
    }
    Enzalutamide "1" -- "1..2" CoFormer : forms
    CoAmorphousSystem -- Enzalutamide
    CoAmorphousSystem -- CoFormer

Derivative 1.3: Ternary Dispersions with Plasticizers/Surfactants

Enabling Description: The binary enzalutamide-polymer dispersion is improved by the inclusion of a third component directly into the spray-dried or extruded solid. A pharmaceutically acceptable plasticizer (e.g., triethyl citrate, polyethylene glycol 400) is added to the spray solution or hot-melt extrusion feed to lower the processing temperature, reducing the risk of thermal degradation of enzalutamide. Alternatively, a surfactant (e.g., D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS), polysorbate 80) is incorporated to act as a dissolution enhancer and a crystallization inhibitor in the aqueous use environment. The resulting ternary amorphous solid dispersion contains enzalutamide, a concentration-enhancing polymer (e.g., HPMCAS), and a plasticizer/surfactant, providing superior processability and enhanced bioavailability compared to a binary system.

flowchart LR
    subgraph Spray Solution
        A[Enzalutamide]
        B[Polymer: HPMCAS]
        C[Surfactant: TPGS]
    end
    A & B & C --> D{Common Solvent};
    D --> E[Spray Drying];
    E --> F[Ternary Amorphous Dispersion Particles];
    F --> G[Dosage Form];

2. Operational Parameter Expansion

Derivative 2.1: Supercritical Fluid Processing for Solvent-Free Dispersions

Enabling Description: The amorphous solid dispersion is prepared using a supercritical fluid (SCF) process to avoid the use of organic solvents. Enzalutamide and a suitable polymer (e.g., PVP-VA) are placed in a high-pressure vessel. Supercritical carbon dioxide (scCO2) at a pressure >73.8 bar and temperature >31.1 °C is used as the processing fluid. The scCO2 plasticizes the polymer, lowering its Tg and allowing enzalutamide to dissolve or disperse within the molten polymer at a relatively low temperature (e.g., 50-80 °C). The system is then rapidly depressurized, causing the CO2 to evaporate and instantly solidifying the mixture into a homogeneous amorphous dispersion. This solvent-free method is advantageous for thermally labile drugs and reduces residual solvent concerns.

stateDiagram-v2
    [*] --> Pressurize_Heat: Load Enzalutamide + Polymer
    Pressurize_Heat --> Supercritical: Inject CO2, T > 31.1C, P > 73.8 bar
    Supercritical --> Mixing: Drug dissolves in plasticized polymer
    Mixing --> Depressurize: Rapid pressure release
    Depressurize --> Solid_Dispersion: CO2 evaporates, mixture solidifies
    Solid_Dispersion --> [*]: Collect powder

Derivative 2.2: Point-of-Care Formulation via Electrospraying/Electrospinning

Enabling Description: For personalized medicine, a miniaturized device utilizes electrohydrodynamic atomization to produce the enzalutamide dispersion at the point of care. A solution containing enzalutamide, a polymer, and a volatile solvent is fed through a nozzle maintained at a high electrical potential (5-30 kV) relative to a grounded collector plate. The strong electric field overcomes the solution's surface tension, forming a Taylor cone and emitting a fine jet. For electrospraying, the jet breaks into highly charged droplets, which dry rapidly to form amorphous micro- or nanoparticles. For electrospinning, the jet solidifies into a continuous fiber. The resulting particles or fiber mat can be collected on an edible substrate for immediate oral administration, allowing for precisely tailored patient-specific dosing.

sequenceDiagram
    participant Pharmacist
    participant ElectrospinningDevice
    participant Patient
    Pharmacist->>ElectrospinningDevice: Load drug-polymer solution & dose info
    activate ElectrospinningDevice
    ElectrospinningDevice->>ElectrospinningDevice: Apply high voltage (20kV)
    ElectrospinningDevice->>ElectrospinningDevice: Extrude solution as fiber onto edible film
    ElectrospinningDevice-->>Pharmacist: Dispense dose-loaded film
    deactivate ElectrospinningDevice
    Pharmacist->>Patient: Administer personalized dose

3. Cross-Domain Application

Derivative 3.1: Agrochemical Application - Enhanced Bioavailability of Fungicides

Enabling Description: A poorly water-soluble fungicide, such as azoxystrobin, is formulated as a solid amorphous dispersion with an environmentally safe, water-soluble polymer (e.g., polyvinyl alcohol, lignin derivatives). The fungicide and polymer are co-dissolved in a solvent and spray-dried to produce a water-dispersible granule (WDG). When added to a spray tank, the granules dissolve to form a supersaturated solution of the fungicide. This enhances the adhesion to plant cuticles and increases the rate of absorption into the plant tissue, leading to improved efficacy at lower application rates and reduced environmental runoff of crystalline pesticide residues.

graph TD
    A[Fungicide: Azoxystrobin]
    B[Polymer: Polyvinyl Alcohol]
    A & B --> C{Spray Drying};
    C --> D[Water-Dispersible Granule];
    D --> E{Add to Water Spray Tank};
    E --> F[Supersaturated Fungicide Solution];
    F --> G[Application to Crops];

Derivative 3.2: Aerospace Application - Stabilization of Organic Sensor Reagents

Enabling Description: A sensitive organic chromophore, used in a life-detection instrument for a Mars rover, is stabilized for long-term storage and exposure to radiation and extreme temperature fluctuations. The chromophore is formulated as a solid amorphous dispersion with a high-Tg, radiation-resistant polymer such as polyimide or a specialized grade of HPMCAS. The dispersion is created via spray-drying and deposited as a thin film on the surface of an optical sensor. The polymer matrix immobilizes the chromophore, preventing photo-bleaching, thermal degradation, and crystallization, ensuring the sensor remains calibrated and functional throughout a multi-year deep-space mission.

classDiagram
    class SensorSystem {
        +missionDuration: "4 years"
        +operatingTemp: "-70C to +20C"
    }
    class OrganicChromophore {
        -isSensitiveToRadiation: true
        -isThermallyLabile: true
    }
    class StabilizingPolymer {
        <<High-Tg>>
        +polymer: Polyimide
        +glassTransitionTemp: "> 200C"
    }
    SensorSystem "1" *-- "1" OrganicChromophore : contains
    OrganicChromophore "1" -- "1" StabilizingPolymer : dispersedIn

Derivative 3.3: Food Science Application - Bioavailability of Nutraceuticals

Enabling Description: A poorly bioavailable nutraceutical, such as curcumin or coenzyme Q10, is formulated as a solid amorphous dispersion using a food-grade polymer (e.g., hydroxypropyl methylcellulose, gum arabic). The process involves hot-melt extrusion of the nutraceutical and polymer, producing a solid extrudate which is then milled into a fine powder. This powder is incorporated into functional foods, such as protein bars or beverage mixes. The amorphous dispersion significantly increases the solubility and subsequent absorption of the nutraceutical in the gastrointestinal tract, allowing for a demonstrably higher clinical effect from a lower dose compared to the crystalline form.

flowchart TD
    subgraph Hot-Melt Extrusion
        A[Nutraceutical: Curcumin]
        B[Food-Grade Polymer: HPMC]
    end
    A & B --> C[Extruder];
    C --> D[Solid Extrudate];
    D --> E[Milling];
    E --> F[Amorphous Dispersion Powder];
    F --> G{Incorporate into Protein Bar};

4. Integration with Emerging Tech

Derivative 4.1: AI-Driven Continuous Manufacturing Process Control

Enabling Description: A continuous manufacturing line for amorphous solid dispersions, using hot-melt extrusion, is controlled by a machine learning model. In-line Process Analytical Technology (PAT) sensors, including Near-Infrared (NIR) and Raman spectroscopy probes, monitor the extrudate in real-time. The spectral data feeds into a pre-trained convolutional neural network (CNN) that predicts the degree of amorphicity and drug content uniformity. The AI controller dynamically adjusts process parameters—such as extruder screw speed, barrel temperature profile, and feed rate—to maintain the product within predefined quality specifications, minimizing batch-to-batch variability and enabling real-time release.

graph LR
    A[API + Polymer Feed] --> B(Hot-Melt Extruder);
    B --> C[Extrudate];
    C -- Real-time data --> D(PAT Sensors - NIR/Raman);
    D -- Spectral Data --> E(AI Control System - CNN);
    E -- Adjusts Parameters --> B;
    C --> F[Finished Dosage Form];

Derivative 4.2: IoT-Enabled Smart Packaging for Stability Monitoring

Enabling Description: A pharmaceutical blister pack or bottle is equipped with a printed, disposable sensor label containing IoT connectivity (e.g., NFC, low-power Bluetooth). The sensor monitors the micro-environment within the package, specifically temperature and relative humidity. The data is logged at regular intervals. When a patient or pharmacist scans the package with a smartphone, the data is uploaded to a cloud database. An algorithm assesses the cumulative environmental exposure against the known stability profile of the specific amorphous dispersion (based on its Tg vs. humidity curve). The system can then issue an alert if the product's stability has been compromised, preventing the administration of a potentially sub-potent or crystallized drug product.

sequenceDiagram
    participant IoT_Sensor
    participant Smartphone
    participant Cloud_Platform
    participant Patient
    loop Periodic Logging
        IoT_Sensor->>IoT_Sensor: Log Temp & Humidity
    end
    Patient->>Smartphone: Scan package (NFC)
    Smartphone->>IoT_Sensor: Request data
    IoT_Sensor-->>Smartphone: Transmit stored data
    Smartphone->>Cloud_Platform: Upload environmental history
    activate Cloud_Platform
    Cloud_Platform->>Cloud_Platform: Analyze data against stability model
    Cloud_Platform-->>Smartphone: Send Status (OK / Alert)
    deactivate Cloud_Platform
    Smartphone->>Patient: Display product status

5. The "Inverse" or Failure Mode

Derivative 5.1: Triggered-Crystallization for On-Demand Inactivation

Enabling Description: A solid amorphous dispersion of enzalutamide is formulated with a photocatalytic excipient (e.g., titanium dioxide nanoparticles) incorporated into the polymer matrix. The formulation is stable under normal storage conditions and amber packaging. However, upon exposure to a specific wavelength of UV light (e.g., 365 nm), the photocatalyst generates localized heat or reactive species that act as nucleation sites, triggering rapid conversion of the amorphous drug to its stable, less-soluble crystalline form. This serves as a fail-safe mechanism for disposal. An "inactivation device" could expose returned or expired tablets to UV light, rendering the API poorly bioavailable and environmentally safer for disposal.

stateDiagram-v2
    state Amorphous {
        description: High Bioavailability
    }
    state Crystalline {
        description: Low Bioavailability
    }
    Amorphous --> Crystalline: UV Light (365nm) exposure
    [*] --> Amorphous: Formulation
    Crystalline --> [*]: Inactivated for Disposal

Combination Prior Art Scenarios

AI Formulation with Open-Source Standards: The AI-driven process control system (Derivative 4.1) is implemented using the TensorFlow open-source machine learning framework. The disclosure includes the Python code for a convolutional neural network model architecture designed to accept 1D spectral data from a PAT sensor as input and output a classification of "amorphous," "partially crystalline," or "crystalline," along with a regression value for predicted drug concentration. The model is trained on a public dataset of polymer/API spectra.
IoT Stability Monitoring with Open-Source Protocols: The IoT-enabled smart packaging system (Derivative 4.2) is built entirely on open-source standards. The sensor communicates using the MQTT (Message Queuing Telemetry Transport) protocol over Bluetooth Low Energy. The data is transmitted to a cloud server running an instance of the ThingsBoard open-source IoT platform, which provides data collection, processing, and visualization dashboards for monitoring the stability of entire batches of the pharmaceutical product throughout the supply chain.
Blockchain-Verified Supply Chain with Open-Source Ledger: The authenticity and stability of the enzalutamide dispersion are tracked using a decentralized application built on the Hyperledger Fabric open-source blockchain framework. A smart contract (chaincode) is disclosed, which defines the on-chain logic. The contract requires that for a batch to be validated, the manufacturing parameters from the extruder, the lot numbers of the API and polymer, and a hash of the IoT stability data (from Derivative 4.2) must all be recorded as transactions on the immutable ledger. This creates a verifiable "digital passport" for each batch, preventing counterfeiting and ensuring quality.